Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 321 participants.

Also called NCT04811092

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 321 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04811092
  • EU CT 2023-509139-16-00
  • WHO UTN U1111-1309-6312
  • EudraCT 2021-000199-12
Other papers using this trial's data
  • Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis The New England journal of medicine, 2025-10-23 DOI, PubMed 41025556

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Serbia, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04811092. Randomized; double masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2025-04-03 (actual). Results posted on 2026-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Acronym
HYPERION
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Sotatercept
Intervention (Other)
Placebo
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (class: industry)

Record details

Record id
cardio:ct-nct04811092
Content hash
a56c86c828f046f32f48134e647c3bd0fc743210c40f7c868a42ddc24bcc767b